Page last updated: 2024-09-03
alpha-(n6-adenyl)styrene oxide and 2-[[5-(1-benzotriazolylmethyl)-1,3,4-oxadiazol-2-yl]thio]-N-[(4-fluorophenyl)methyl]-N-phenylacetamide
alpha-(n6-adenyl)styrene oxide has been researched along with 2-[[5-(1-benzotriazolylmethyl)-1,3,4-oxadiazol-2-yl]thio]-N-[(4-fluorophenyl)methyl]-N-phenylacetamide in 1 studies
Compound Research Comparison
Studies (alpha-(n6-adenyl)styrene oxide) | Trials (alpha-(n6-adenyl)styrene oxide) | Recent Studies (post-2010) (alpha-(n6-adenyl)styrene oxide) | Studies (2-[[5-(1-benzotriazolylmethyl)-1,3,4-oxadiazol-2-yl]thio]-N-[(4-fluorophenyl)methyl]-N-phenylacetamide) | Trials (2-[[5-(1-benzotriazolylmethyl)-1,3,4-oxadiazol-2-yl]thio]-N-[(4-fluorophenyl)methyl]-N-phenylacetamide) | Recent Studies (post-2010) (2-[[5-(1-benzotriazolylmethyl)-1,3,4-oxadiazol-2-yl]thio]-N-[(4-fluorophenyl)methyl]-N-phenylacetamide) |
---|---|---|---|---|---|
8 | 0 | 2 | 6 | 0 | 1 |
Protein Interaction Comparison
Protein | Taxonomy | alpha-(n6-adenyl)styrene oxide (IC50) | 2-[[5-(1-benzotriazolylmethyl)-1,3,4-oxadiazol-2-yl]thio]-N-[(4-fluorophenyl)methyl]-N-phenylacetamide (IC50) |
---|---|---|---|
galanin receptor type 3 | Homo sapiens (human) | 1.2375 | |
COUP transcription factor 2 isoform a | Homo sapiens (human) | 4.873 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Butkiewicz, M; Lowe, EW; Meiler, J; Mendenhall, JL; Mueller, R; Teixeira, PL; Weaver, CD | 1 |
Other Studies
1 other study(ies) available for alpha-(n6-adenyl)styrene oxide and 2-[[5-(1-benzotriazolylmethyl)-1,3,4-oxadiazol-2-yl]thio]-N-[(4-fluorophenyl)methyl]-N-phenylacetamide
Article | Year |
---|---|
Benchmarking ligand-based virtual High-Throughput Screening with the PubChem database.
Topics: Algorithms; Animals; Area Under Curve; Computer Simulation; Databases, Chemical; Decision Trees; Drug Discovery; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Neural Networks, Computer; Quality Improvement; Quantitative Structure-Activity Relationship; ROC Curve; Support Vector Machine | 2013 |